Feraheme® suppresses immune function of human T lymphocytes through mitochondrial damage and mitoROS production

Toxicology and Applied Pharmacology

Volumn 350, Issue , 2018, Pages 52-63

  Shah, Ankit ^a   Mankus, Cassandra I ^a   Vermilya, Alison M ^a   Soheilian, Ferri ^a   Clogston, Jeffrey D ^a   Dobrovolskaia, Marina A ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Immunosuppression; Immunotoxicity; Iron oxide; Nanoparticles; T Cells

Indexed keywords

CASPASE 3; CASPASE 9; CD71 ANTIGEN; FERROPORTIN; FERUMOXYTOL; REACTIVE OXYGEN METABOLITE; FERRIC ION; FERRIC OXIDE; METAL NANOPARTICLE;

ARTICLE; CELL DAMAGE; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTOXICITY; IN VITRO STUDY; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY; LYMPHOCYTE FUNCTION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NORMAL HUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIMARY CELL; T LYMPHOCYTE; WESTERN BLOTTING; CELL CULTURE; CELLULAR IMMUNITY; DRUG EFFECT; METABOLISM; PHYSIOLOGY; TRANSFORMED CELL LINE; TUMOR CELL LINE;

CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELLS, CULTURED; FERRIC COMPOUNDS; HUMANS; IMMUNITY, CELLULAR; MEMBRANE POTENTIAL, MITOCHONDRIAL; METAL NANOPARTICLES; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES;

EID: 85046730968     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2018.04.028     Document Type: Article

References (48)

1. Beguin, Y., Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin. Chim. Acta 329:1–2 (2003), 9–22.
2. Ben-Bassat, H., Shlomai, Z., Kohn, G., Prokocimer, M., Establishment of a human T-acute lymphoblastic leukemia cell line with a (16;20) chromosome translocation. Cancer Genet. Cytogenet. 49:2 (1990), 241–248.
3. Bennett, S.J., Griffiths, H.R., Regulation of T-Cell Functions by Oxidative Stress. Alcaraz, M.J., Gualillo, O., Sánchez-Pernaute, O., (eds.) Studies on Arthritis and Joint Disorders, 2013, Springer New York, New York, NY, 33–48.
4. Cecchini, G., Function and structure of complex II of the respiratory chain. Annu. Rev. Biochem. 72 (2003), 77–109.
5. Chen, C.L., Zhang, H., Ye, Q., Hsieh, W.Y., Hitchens, T.K., Shen, H.H. et al., A new nano-sized iron oxide particle with high sensitivity for cellular magnetic resonance imaging. Mol. Imaging Biol. 13:5 (2011), 825–839.
6. Di Gioacchino, M., Petrarca, C., Lazzarin, F., Di Giampaolo, L., Sabbioni, E., Boscolo, P. et al., Immunotoxicity of nanoparticles. Int. J. Immunopathol. Pharmacol. 24:1 Suppl (2011), 65S–71S.
7. Easo, S.L., Mohanan, P.V., In vitro hematological and in vivo immunotoxicity assessment of dextran stabilized iron oxide nanoparticles. Colloids Surf B Biointerfaces 134 (2015), 122–130.
8. Eleftheriadis, T., Pissas, G., Liakopoulos, V., Stefanidis, I., Cytochrome c as a potentially clinical useful marker of mitochondrial and cellular damage. Front. Immunol., 7, 2016, 279.
9. FERAHEME® (ferumoxytol) Injection [package insert], AMAG Pharmaceuticals, Inc. Waltham, MA. 2015.
10. Gaharwar, U.S., Meena, R., Rajamani, P., Iron oxide nanoparticles induced cytotoxicity, oxidative stress and DNA damage in lymphocytes. J. Appl. Toxicol. 37:10 (2017 Oct), 1232–1244, 10.1002/jat.3485.
11. George, M.P., Masur, H., Norris, K.A., Palmer, S.M., Clancy, C.J., McDyer, J.F., Infections in the immunosuppressed host. Ann Am Thorac Soc. 11:Suppl. 4 (2014), S211–20.
12. Ghirelli, C., Hagemann, T., Targeting immunosuppression for cancer therapy. J. Clin. Invest. 123:6 (2013), 2355–2357.
13. Grosse, S., Stenvik, J., Nilsen, A.M., Iron oxide nanoparticles modulate lipopolysaccharide-induced inflammatory responses in primary human monocytes. Int. J. Nanomedicine 11 (2016), 4625–4642.
14. Hempel, J.C., Poppelaars, F., Gaya da Costa, M., Franssen, C.F.M., de Vlaam, T.P.G., Daha, M.R. et al., Distinct in vitro complement activation by various intravenous iron preparations. Am. J. Nephrol. 45:1 (2017), 49–59.
15. Jahn, M.R., Andreasen, H.B., Futterer, S., Nawroth, T., Schunemann, V., Kolb, U. et al., A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78:3 (2011), 480–491.
16. Juo, P., Kuo, C.J., Yuan, J., Blenis, J., Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 8:18 (1998), 1001–1008.
17. Kalyanaraman, V.S., Sarngadharan, M.G., Robert-Guroff, M., Miyoshi, I., Golde, D., Gallo, R.C., A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 218:4572 (1982), 571–573.
18. Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P. et al., Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology, 3(9), 2014, e955691.
19. Kroemer, G., Galluzzi, L., Brenner, C., Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87:1 (2007), 99–163.
20. Lenaz, G., Role of mitochondria in oxidative stress and ageing. Biochim. Biophys. Acta 1366:1–2 (1998), 53–67.
21. Li, Y.Q., Yan, H., Bai, B., Change in iron transporter expression in human term placenta with different maternal iron status. Eur. J. Obstet. Gynecol. Reprod. Biol. 140:1 (2008), 48–54.
22. Li, K., Nejadnik, H., Daldrup-Link, H.E., Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics. Drug Discov. Today 22:9 (2017), 1421–1429.
23. Lill, R., Hoffmann, B., Molik, S., Pierik, A.J., Rietzschel, N., Stehling, O. et al., The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim. Biophys. Acta 1823:9 (2012), 1491–1508.
24. Lu, M., Cohen, M.H., Rieves, D., Pazdur, R., FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 85:5 (2010), 315–319.
25. Lunov, O., Syrovets, T., Buchele, B., Jiang, X., Rocker, C., Tron, K. et al., The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials 31:19 (2010), 5063–5071.
26. Naqvi, S., Samim, M., Abdin, M., Ahmed, F.J., Maitra, A., Prashant, C. et al., Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int. J. Nanomedicine 5 (2010), 983–989.
27. Nedyalkova, M., Donkova, B., Romanova, J., Tzvetkov, G., Madurga, S., Simeonov, V., Iron oxide nanoparticles - in vivo/in vitro biomedical applications and in silico studies. Adv. Colloid Interface Sci. 249 (2017 Nov), 192–212, 10.1016/j.cis.2017.05.003.
28. Ow, Y.P., Green, D.R., Hao, Z., Mak, T.W., Cytochrome c: functions beyond respiration. Nat. Rev. Mol. Cell Biol. 9:7 (2008), 532–542.
29. Pai, A.B., Conner, T., McQuade, C.R., Olp, J., Hicks, P., Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 24:4 (2011), 603–613.
30. Park, E.J., Choi, D.H., Kim, Y., Lee, E.W., Song, J., Cho, M.H. et al., Magnetic iron oxide nanoparticles induce autophagy preceding apoptosis through mitochondrial damage and ER stress in RAW264.7 cells. Toxicol. in Vitro 28:8 (2014), 1402–1412.
31. Park, E.J., Oh, S.Y., Lee, S.J., Lee, K., Kim, Y., Lee, B.S. et al., Chronic pulmonary accumulation of iron oxide nanoparticles induced Th1-type immune response stimulating the function of antigen-presenting cells. Environ. Res. 143:Pt A (2015), 138–147.
32. Penna, C., Perrelli, M.G., Pagliaro, P., Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid. Redox Signal. 18:5 (2013), 556–599.
33. Perelman, A., Wachtel, C., Cohen, M., Haupt, S., Shapiro, H., Tzur, A., JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis., 3, 2012, e430.
34. Pouliquen, D., Le Jeune, J.J., Perdrisot, R., Ermias, A., Jallet, P., Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn. Reson. Imaging 9:3 (1991), 275–283.
35. Rosager, A.M., Sorensen, M.D., Dahlrot, R.H., Hansen, S., Schonberg, D.L., Rich, J.N. et al., Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: expression and prognostic value. PLoS One, 12(8), 2017, e0182954.
36. Sabareeswaran, A., Ansar, E.B., Harikrishna Varma, P.R., Mohanan, P.V., Kumary, T.V., Effect of surface-modified superparamagnetic iron oxide nanoparticles (SPIONS) on mast cell infiltration: an acute in vivo study. Nanomedicine 12:6 (2016), 1523–1533.
37. Sadauskas, E., Danscher, G., Stoltenberg, M., Vogel, U., Larsen, A., Wallin, H., Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine 5:2 (2009), 162–169.
38. Shah, A., Dobrovolskaia, M.A., Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: therapeutic benefits, toxicity, mechanistic insights, and translational considerations. Nanomedicine 14:3 (2018), 977–990.
39. Shen, C.C., Wang, C.C., Liao, M.H., Jan, T.R., A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int. J. Nanomedicine 6 (2011), 1229–1235.
40. Shen, C.C., Liang, H.J., Wang, C.C., Liao, M.H., Jan, T.R., A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression. Int. J. Nanomedicine 6 (2011), 2791–2798.
41. Shen, C.C., Liang, H.J., Wang, C.C., Liao, M.H., Jan, T.R., Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int. J. Nanomedicine 7 (2012), 2729–2737.
42. Turcheniuk, K., Tarasevych, A.V., Kukhar, V.P., Boukherroub, R., Szunerits, S., Recent advances in surface chemistry strategies for the fabrication of functional iron oxide based magnetic nanoparticles. Nano 5:22 (2013), 10729–10752.
43. Umbreit, T.H., Francke-Carroll, S., Weaver, J.L., Miller, T.J., Goering, P.L., Sadrieh, N. et al., Tissue distribution and histopathological effects of titanium dioxide nanoparticles after intravenous or subcutaneous injection in mice. J. Appl. Toxicol. 32:5 (2012), 350–357.
44. Valdiglesias, V., Fernandez-Bertolez, N., Kilic, G., Costa, C., Costa, S., Fraga, S. et al., Are iron oxide nanoparticles safe? Current knowledge and future perspectives. J. Trace Elem. Med. Biol. 38 (2016), 53–63.
45. Wysowski, D.K., Swartz, L., Vicky Borders-Hemphill, B., Goulding, M.R., Dormitzer, C., Use of parenteral iron products and serious anaphylactic-type reactions. Am. J. Hematol. 85:9 (2010), 650–654.
46. Yan, L., Liu, X., Liu, W.X., Tan, X.Q., Xiong, F., Gu, N. et al., Fe2O3 nanoparticles suppress Kv1.3 channels via affecting the redox activity of Kvbeta2 subunit in Jurkat T cells. Nanotechnology, 26(50), 2015, 505103.
47. Youle, R.J., van der Bliek, A.M., Mitochondrial fission, fusion, and stress. Science 337:6098 (2012), 1062–1065.
48. Zhu, M.T., Wang, B., Wang, Y., Yuan, L., Wang, H.J., Wang, M. et al., Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: risk factors for early atherosclerosis. Toxicol. Lett. 203:2 (2011), 162–171.